anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
A spreader for spreading granular and/or powdery materials having a hopper and rotary distribution members with ejection blades on plates located below the hopper. The areas covered by the two distribution members can be adjusted so that they substantially coincide with one another. In some embodiments, the orientation of the ejection blades on the plates can be adjusted. Material flows to the distribution members through feeding means that include outlet openings and ports that can be in register with the openings. Also, displacers or closing members for affecting this flow can be positioned near the outlets at the lower portion of the hopper. A transmission, including change speed gears, can be connected through endless flexible members, i.e., ropes or belts to the shafts mounting the distribution members.
Status EPILEPTICUS (SE) is a major medical emergency. The incidence per 100,000 population has been estimated at 9.9 episodes in Europe and 41 episodes in the US. The overall morbidity and mortality associated with convulsive SE (CSE) is 60% at three months. The alteration of functional prognosis of these patients is more conventionally attributed to the cause than to CSE itself. Longer seizure duration, progression to refractory status EPILEPTICUS and presence of cerebral insult are strong factors independently associated with a poor functional outcome. These three factors offer may be amenable to improvement and hope for preventive strategies. Current guidelines recommend the use of anticonvulsant treatment whose goal is prompt cessation of clinical and electrical seizures. None of these treatments has demonstrated NEUROPROTECTICE property. Therapeutic moderate hypothermia (between 32 and 34 ° C) showed interest in neuroprotection of post anoxic coma patients after a cardiovascular arrest on ventricular fibrillation by reducing morbidity and mortality in about 20% without major side effects. This technique has been used successfully in various pathologies such as stroke or traumatic brain injury. Pathophysiological mechanisms involved in epileptogenesis and neurotoxicity induced by persistence of seizures can be blocked by therapeutic hypothermia. Recent work on experimental models of SE demonstrated neuroprotective and anticonvulsant interest of therapeutic hypothermia. Therapeutic hypothermia has also been successfully used in some cases of particularly refractory CSE. Its early use in patients with SE would have a double interest: neuroprotective and anticonvulsant. There is currently no published studies or ongoing to determine the interest of its early use in patients with CSE.

Thus, the current study AIMAS at evaluating the effectiveness of the implementation of a procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours, to reduce morbidity and mortality at 3 months (+ / - 1 week) in mechanically ventilated ICU patients with convulsive status EPILEPTICUS.
A method for preparing platelet-enriched blood plasma comprises sampling the blood from a donor, se[parathion of the cells by centrifugation. The layer of platelets is collected into the separate container. The separaton solution is prepared consisting of Ficoll-400 and a component selected among Verografin, Isopaque, Urografin, Urotrast, Uropolonium, Uromiro, Nisotrast-370, Triosyl, Paque, Omnipaque or Ronpaquon. The blood is layered onto the separation mixture stated above. After the first centrifugation, the upper layer of plasma is removed, and the second centrifugation follows. The layer of platelets is collected into the separate container.
When a patient presents to the Maternal Hypertension Center at Cabell Huntington Hospital, she will receive a non-invasive hemodynamic assessment via the NICaS system as per usual protocol. The NICaS system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. In typical practice, the vasodilator nifedipine is initiated for increased systemic vascular resistance and elevated cardiac output is treated with beta blockade (via either atenolol or labetalol). The medication to be given to each subject will be based on their hemodynamics. Specifically, nifedipine will be given for a mean arterial pressure \>100 and a beta blocker will be given for a cardiac output \>8 l/min. The patients will be asked to return in one week for repeat ICG measurement.
The importance of the width of keratinized mucosa (KM) at implant sites remains a subject of ongoing debate. Reduced dimensions of KM (width \<2 mm) are associated with mucosal recession, biofilm accumulation, soft-tissue inflammation, marginal bone loss, peri-implantitis and patient discomfort. Surgical options to increase the width of KM include an apically positioned flap, either alone or in combination with an autogenous graft or a xenogeneic collagen matrix. The free gingival graft (FGG) is a well-established technique with a history of successful clinical use. The harvesting procedure for autogenous graft from the palatal mucosa, however, is usually associated with significant patient morbidity, especially when there is a need to graft extensive mucosal areas. To overcome this problem, various graft modifications have been proposed to limit the need for large-area autografts. Examples include the accordion technique, the strip gingival autograft technique, and a vertical modification of the strip gingival graft. The expanded mesh graft, another graft modification, has been used in the field of plastic surgery, especially in the treatment of large burn wounds. Recently, De Greef, Carcuac, De Mars et al. proposed this technique to be used in periodontal plastic surgery, more specifically, in the widening of KM at implant sites by means of a meshed free gingival graft (mesh-FGG). In this case series, initially inadequate width of KM in edentulous areas could be successfully increased prior to implant installation, without the need for any extensive autograft harvesting. Data from trials comparing mesh-FGG to conventional FGG and assessing the long-term efficacy of this novel technique, however, are missing.

The investigators hypothesize that the mesh-FGG technique will demonstrate similar clinical results (non-inferiority: increase in KM width) but improved patient-reported outcomes (superiority: post-surgical morbidity) compared to the FGG.
Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
The invention relates to a spray for clearing fire and relieving sore-throat, belonging to the technical field of a medicinal product. The constituents of the spray for clearing fire and relieving sore-throat are as follows: formosan lattuce herb, flos lonicerae, mirabilitum praeparatum, herba andrographitis, radix angelicae, periostracum cicada, selfheal and menthol crystal, and the spray is obtained by extracting and concentrating the raw materials at low temperature. The spray has the effects of clearing away heat and toxic materials, cooling blood and diminishing swelling, and the spray for clearing fire and relieving sore-throat is directly sprayed on the pharynx oralis of the crowds suffering from swelling and pain in throat, throat itching, hoarseness and aphtha caused by influenza and sphagitis and the like. The spray for clearing fire and relieving sore-throat directly reaches the focuses on the affected parts with rapid effect, the bioactive constituents permeate the throat histocytes so as to quickly diminish swelling and stop pain. The advantages of the traditional Chinese medicines, namely conditioning and nourishing, are given into play, heat and toxic materials are cleared away, and swelling and pain are relieved, so that the defect that the oral medicine is slow to absorb is overcome. The fresh breath with light fruit flavor is produced after the spray for clearing fire and relieving sore-throat is utilized, the biological activities of the effective components are retained, and the spray for clearing fire and relieving sore-throat is safe and mild and free from side effects.
The thioester of N-acetyl-cysteine with p-isobutylphenyl- propionic acid shows simultaneous anti-inflammatory and mucolytic activity. It is prepared by the reaction of a reactive derivative of p-isobutylphenylpropionic acid and N-acetyl-cysteine at low temperature in a polar solvent. Salts with organic and inorganic bases, with basic amino acids and with basic antibiotics which have a macromolecular structure are stable and generally soluble in water, as a result of which the active ingredient according to the invention can be formulated for oral, parenteral, rectal and topical administration. This invention relates to a thioester of N-acetyl- cysteine propionyl glycine with p-isobutylphenylpropionic acid, which has the formula: <IMAGE> and which has useful anti-inflammatory and mucolytic properties, and its pharmacologically acceptable non- toxic salts. The anti-inflammatory activity of p- isobutylphenylpropionic acid is known, and the disadvantages from the point of view of its therapeutic use are also known. The compound according to the invention, as such or converted into a salt with organic bases containing alkaline or alkaline earth ions, or with basic amino acids such as arginine and lysine, or with the nuclei of basic antibiotics such as erythromycin and propionyl erythromycin, demonstrate useful properties as they have anti-inflammatory and mucolytic activity at the same time. This invention also relates to processes for the preparation of the subject compound which are characterised in that a p-isobutylphenylpropionic acid halide and a derivative of N-acetyl-cysteine are caused to react in a medium which has an alkaline pH containing a polar solvent, preferably water or mixtures of water and dioxan, at low temperature, giving rise to a low melting point thioester which is an odourless pale yellow oil at ambient temperature. The reaction product as such is free from impurities and is used in the reaction to form the salt with the various bases mentioned above in order to obtain the corresponding salts, which are stable, water-soluble and easy to use in the pharmaceutical field.
Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
Multi-drug resistant  tuberculosis  (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-#-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty pβCD are able to impair  M. tuberculosis  (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence. Taken together, the results suggest that materials made of cross-linked β-cyclodextrins (e.g. nanoparticles) loaded or not with antibiotics play an antibacterial action by its own and could be used as carrier in drug regimen formulations effective against TB.20
Timolol maleate is a beta 1and beta 2(non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. 

Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.

Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with asthma or other bronchospastic conditions is potentially dangerous.

ISTALOL ophthalmic solution, when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage.

The onset of reduction in intraocular pressure following administration of ISTALOL can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure lowering effect of ISTALOL is well maintained.

The precise mechanism of the ocular hypotensive action of ISTALOL is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.
No intervention administered. Eligible zip codes (n=96) will be randomized using stratified randomization at the state level.
The present invention is a method of preparation of standardized ethanolic and aqueous plant extract powder from  Ilex paraguariensis  leaves   for human or veterinary use .  The present invention also provides the identification of compounds including rutin, caffeine, theobromine, theophylline and caffeoylquinic acid and its isomers quantified as chlorogenic acids, particularly obtained from a standardized aqueous or ethanolic extract from  Ilex paraguariensis  plant. The extract of  Ilex paraguariensis  plant is rich in methylxanthines such as caffeine, theobromine and theophylline which presented good oral bioavailability. Moreover, the present invention describes the use of  Ilex paraguariensis  plant extract for the   preventive and/or therapeutic treatment of obesity and related metabolic diseases, including type 2 diabetes, hypertension, heart disease, lipid dysfunction, non-alcoholic fatty liver disease (steatosis), inflammatory diseases and other related diseases associated with metabolic syndrome. Moreover, the extract of  Ilex paraguariensis  plant was safe (no toxic) and not mutagenic when tested  in vivo . The mechanism of action by which extract of  Ilex paraguariensis  plant improved obesity and metabolic syndrome seems to be related with the up or down regulation of most relevant genes in peripheral organs and in the central nervous system, altering cellular singling pathways involved in such diseases.
Patients should be under close clinical observation when treatment with diazoxide is initiated. Carefully monitor the clinical response and blood glucose until the patient’s condition has stabilized satisfactory; in most instances, this may be accomplished in several days. If administration of diazoxide is not effective after 2 or 3 weeks, discontinue diazoxide.

Individualize the dosage of diazoxide based on the severity of the hypoglycemic condition and the blood glucose level and clinical response of the patient. Adjust the dosage until the desired clinical and laboratory effects are produced with the least amount of diazoxide. Take special care to ensure the accuracy of the dosage in infants and young children.
The pain-free TMD group consisted of 30 children between 7.3 and 12.6 years of age. To be included in the pain-free TMD group the participants had to meet Axis I of the RDC/TMD criteria for a pain-free diagnosis.
Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).
Liquid biopsy to provide a mutational snapshot of diffuse large B-cell lymphoma is an emerging technology of exciting potential utility. The report by Alcoceba et al. assesses the tractability of the EuroClonality-NDC assay to profile lymphoma using cell-free DNA and highlights the prognostic implication of attaining a major molecular response to therapy. Commentary on: Alcoceba et al. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease. Br J Haematol 2024;205:109-121.
T cells have the power to destroy malignant cells under certain conditions, as demonstrated by the rare spontaneous remissions of cancer. However, the endogenous T cell response to cancer fails in the vast majority of patients and the tolerogenic conditions within the liver may pose additional immunologic barriers for those with intrahepatic metastases. The investigators modify patient T cells to kill malignant cells based on their expression of tumor antigens using antibody-defined recognition. The investigators will achieve this by preparing chimeric IgCD28TCR genes in mammalian expression vectors to yield "designer T cells" from normal patient cells. Prior studies in model systems demonstrated that recombinant IgCD28TCR could direct modified T cells to respond to antigen targets with IL2 secretion, cellular proliferation, and cytotoxicity - the hallmarks of an effective, self-sustaining immune response.

The present trial will test the regional infusion of anti-CEA designer T cells, given via the hepatic artery using a percutaneous approach. This is an intra-patient dose escalation trial, where patients will receive three doses over the course of six weeks. Doses are 10\^8, 10\^9 and 10\^10 modified T cells. Patients are monitored for safety and response. Patients are on-study for one month after dosing.
Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
<P>PROBLEM TO BE SOLVED: To contribute to improvement for easy reading and grasping of respective character strings along a time axis.  <P>SOLUTION: This document processor 1 is provided with a receipt part 100, a character string extraction part 110, a similarity calculation part 130, an importance calculation part 140, and an important character string specification part 150. For each character string, the similarity calculation part 130 calculates a degree of similarity of one character string extracted by the character string extraction part 110 with another character string as a degree of similarity. The importance calculation part 140 calculates importance of one character string based on the degree of similarity between one character string and a predetermined number of character strings temporally before/after the character string. Then, the important character string specification part 150 specifies a character string matching the importance when the importance calculated by the importance calculation part 140 exceeds a threshold value.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: Despite laparoscopic cholecystectomy (LC) is a commonly performed operation under ambulatory setting, significant postoperative pain is still a major concern. The ultrasound-guided subcostal approach of transversus abdominis plane (sTAP) blocks and wound infiltration (WI) are both widely practiced techniques to reduce postoperative pain in patients undergoing LC. Although these methods have been shown to relieve postoperative pain effectively, the relative analgesic efficacy between ultrasound-guided sTAP blocks and WI is not well known.
METHODS: We searched PubMed, EMBASE, and CENTRAL to identify all randomized controlled trials (RCTs) comparing ultrasound-guided sTAP block versus WI for postoperative pain control in adult patients undergone LC. The search was performed until May 2023. Primary outcome was defined as 24-hour cumulative opioid consumption. Secondary outcomes were postoperative pain scores and the incidence of postoperative nausea and vomiting (PONV).
RESULTS: Finally, 6 RCTs were included, and data from 314 participants were retrieved. Postoperative 24-hour opioid consumption was significantly lower in ultrasound-guided sTAP group than in the WI group with a mean difference of -6.67 (95% confidence interval: -9.39 to - 3.95). The ultrasound-guided sTAP group also showed significantly lower pain scores. Incidence of PONV did not significantly differ between the 2 groups.
CONCLUSIONS: We conclude that there is low to moderate evidence to advocate that ultrasound-guided sTAP block has better analgesic effects than WI in patients undergoing LC. Further trials are needed with robust methodology and clearly defined outcomes.
The investigators propose to bring a loved one into PE, one of the most researched and efficacious treatments for PTSD, to increase support for PE adherence. The intervention is a 13-session cognitive-behavioral, intimate partner-assisted treatment for PTSD that draws from PE, ICBT, and PE2.
Toxicity (Gasping Syndrome) with Benzyl Alcohol

Serious adverse reactions including fatal reactions and the "gasping syndrome" occurred in premature neonates and infants in the intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 mg/kg/day to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 mmol/L to 1.378 mmol/L). INCRELEX contains 9 mg/mL benzyl alcohol as a preservative.

Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol. Use of INCRELEX in infants is not recommended [see Warnings and Precautions (5.8)].

Safety and effectiveness in pediatric patients below the age of 2 years of age have not been established.